Pharvaris Publishes Review on Bradykinin B2 Receptor Antagonism for Angioedema

Pharvaris (Nasdaq: PHVS) announced the publication of a comprehensive review in Clinical Reviews in Allergy & Immunology, summarizing decades of evidence supporting bradykinin B2 receptor antagonism as a validated therapeutic strategy for angioedema and related diseases. The article highlights the scientific foundation behind targeting this receptor to address unmet medical needs.

By Pharvaris N.V. · GlobeNewsWire · July 22, 2026, 10:50 UTC

Tickers: $PHVS

Topics: angioedema bradykinin B2 receptor Pharvaris therapeutic target

Read the full article at GlobeNewsWire

More World news

Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC
Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC